BerGenBio - NOK 220 million - Private Placement

Arctic Securities acted as Joint Bookrunner in relation to the Private Placement in BerGenBio ASA. Through the Offering, BerGenBio raised gross proceeds of NOK 220 million, which will be used to continue advancing its clinical trial programs with its lead candidate bemcentinib in patients with Acute Myeloid Leukaemia (AML) and Non Small Cell Lung Cancer (NSCLC), manufacturing scale-up of bemcentinib, biomarker and companion diagnostic development, and phase 1b development of tilvestamab (formerly BGB149), as well as for general corporate purposes.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drugs for most aggressive cancers. Ongoing international clinical trials with the Company's lead product BGB324 is in patients with lung cancer and leukaemia. The Company is a world leader in understanding the central role of AXL kinase in driving immune evasion, drug resistance and metastasis, key traits of aggressive cancer and the cause of the majority of cancer-related deaths.

 We are grateful for vote of confidence and congratulate on the successful transaction!

Latest news

  4. Arctic Securities -

    Cavendish Hydrogen ASA - Prospectus

    Cavendish Hydrogen has applied for admission to trading of its shares on the main board of the Oslo Stock Exchange. Arctic Securities AS is acting as joint lead manager. Please find the prospectus in connection with the Listing.

    Read more →